{"id":50202,"date":"2026-03-07T01:30:00","date_gmt":"2026-03-06T18:30:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=50202"},"modified":"2026-03-07T01:30:00","modified_gmt":"2026-03-06T18:30:00","slug":"servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-serviers-rare-oncology-portfolio","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=50202","title":{"rendered":"Servier and Day One Biopharmaceuticals announce acquisition to expand Servier&#8217;s rare oncology portfolio"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2928141\/Servier_DayOne_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b>Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs.\u00a0<\/b><\/li>\n<li><b>Transaction represents total equity value of approximately $2.5 billion.<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">SURESNES, France and BRISBANE, Calif.<\/span>, <span class=\"legendSpanClass\">March 7, 2026<\/span> \/PRNewswire\/ &#8212; Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (&#8220;Day One&#8221;), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>This acquisition will reinforce Servier&#8217;s position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. It strengthens Servier&#8217;s portfolio and expands its oncology pipeline with programs ranging from early stage to phase 3. The combination of Day One&#8217;s scientific expertise with Servier&#8217;s established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide.<\/p>\n<p>&#8220;This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier&#8217;s position in rare oncology,&#8221; <b>said Olivier Laureau, President of Servier<\/b>. &#8220;It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer.&#8221;<\/p>\n<p>&#8220;Servier&#8217;s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One&#8217;s mission to bring medicines to patients of all ages with life threatening diseases&#8221; <b>said Jeremy Bender, Ph.D., chief executive officer of Day One<\/b>. &#8220;Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low\u2013grade glioma. Importantly, Servier&#8217;s dedication to the rare disease community preserves the patient\u2013first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve.&#8221;<\/p>\n<p>Contacts<\/p>\n<p>Servier Group<br \/>Laura Visserias<br \/><a href=\"mailto:laura.visserias.part@servier.com\" target=\"_blank\" rel=\"nofollow\">laura.visserias.part@servier.com<\/a>\u00a0<\/p>\n<p>Day One Biopharmaceuticals<br \/>Media<br \/><a href=\"mailto:media@dayonebio.com\" target=\"_blank\" rel=\"nofollow\">media@dayonebio.com<\/a>\u00a0<\/p>\n<p>PDF &#8211; <a href=\"https:\/\/mma.prnewswire.com\/media\/2928148\/Servier_DayOne.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2928148\/Servier_DayOne.pdf<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2928141\/Servier_DayOne_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><b>Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs.\u00a0<\/b><\/li>\n<li><b>Transaction represents total equity value of approximately $2.5 billion.<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">SURESNES, France and BRISBANE, Calif.<\/span>, <span class=\"legendSpanClass\">March 7, 2026<\/span> \/PRNewswire\/ &#8212; Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (&#8220;Day One&#8221;), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>This acquisition will reinforce Servier&#8217;s position in oncology targeted therapies in line with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. It strengthens Servier&#8217;s portfolio and expands its oncology pipeline with programs ranging from early stage to phase 3. The combination of Day One&#8217;s scientific expertise with Servier&#8217;s established global capabilities advances a shared commitment to delivering innovative solutions for patients worldwide.<\/p>\n<p>&#8220;This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier&#8217;s position in rare oncology,&#8221; <b>said Olivier Laureau, President of Servier<\/b>. &#8220;It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer.&#8221;<\/p>\n<p>&#8220;Servier&#8217;s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One&#8217;s mission to bring medicines to patients of all ages with life threatening diseases&#8221; <b>said Jeremy Bender, Ph.D., chief executive officer of Day One<\/b>. &#8220;Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low\u2013grade glioma. Importantly, Servier&#8217;s dedication to the rare disease community preserves the patient\u2013first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve.&#8221;<\/p>\n<p>Contacts<\/p>\n<p>Servier Group<br \/>Laura Visserias<br \/><a href=\"mailto:laura.visserias.part@servier.com\" target=\"_blank\" rel=\"nofollow\">laura.visserias.part@servier.com<\/a>\u00a0<\/p>\n<p>Day One Biopharmaceuticals<br \/>Media<br \/><a href=\"mailto:media@dayonebio.com\" target=\"_blank\" rel=\"nofollow\">media@dayonebio.com<\/a>\u00a0<\/p>\n<p>PDF &#8211; <a href=\"https:\/\/mma.prnewswire.com\/media\/2928148\/Servier_DayOne.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2928148\/Servier_DayOne.pdf<\/a><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-50202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/50202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50202"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/50202\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}